Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly Baker

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
The Lancet. Oncology|December 22, 2015
Use of antidepressants and breast cancer recurrenceHolly Baker
The Lancet. Oncology|May 3, 2016
PD-1 inhibition in advanced Merkel-cell carcinomaHolly Baker
The Lancet. Oncology|May 7, 2016
Chemoradiotherapy for grade 2 glioma improves survivalHolly Baker
The Lancet. Oncology|July 18, 2017
Questions over the import of radionuclides after BrexitHolly Baker
The Lancet. Oncology|March 15, 2016
Ramucirumab plus docetaxel for urothelial carcinomaHolly Baker
The Lancet. Oncology|December 6, 2016
Two-dose schedule for human papillomavirus vaccineHolly Baker
The Lancet. Oncology|April 8, 2016
Sulindac plus erlotinib for familial adenomatous polyposisHolly Baker
The Lancet. Oncology|December 4, 2015
Genetic mutations in paediatric cancerHolly Baker
The Lancet. Oncology|October 18, 2016
Daratumumab improves survival in multiple myelomaHolly Baker
The Lancet. Oncology|December 14, 2016
Trastuzumab biosimilar shows potential for breast cancerHolly Baker
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|December 22, 2015
Use of antidepressants and breast cancer recurrenceHolly Baker
The Lancet. Oncology|May 3, 2016
PD-1 inhibition in advanced Merkel-cell carcinomaHolly Baker
The Lancet. Oncology|May 7, 2016
Chemoradiotherapy for grade 2 glioma improves survivalHolly Baker
The Lancet. Oncology|July 18, 2017
Questions over the import of radionuclides after BrexitHolly Baker
The Lancet. Oncology|March 15, 2016
Ramucirumab plus docetaxel for urothelial carcinomaHolly Baker
The Lancet. Oncology|December 6, 2016
Two-dose schedule for human papillomavirus vaccineHolly Baker
The Lancet. Oncology|April 8, 2016
Sulindac plus erlotinib for familial adenomatous polyposisHolly Baker
The Lancet. Oncology|December 4, 2015
Genetic mutations in paediatric cancerHolly Baker
The Lancet. Oncology|October 18, 2016
Daratumumab improves survival in multiple myelomaHolly Baker
The Lancet. Oncology|December 14, 2016
Trastuzumab biosimilar shows potential for breast cancerHolly Baker
Pageof 8